We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

WATERS CORPORATION

Waters Corp. designs, manufactures, sells and services ultra performance liquid chromatography (UPLC), high performan... read more Featured Products: More products

Download Mobile App




Ultra-Performance LC-MS System Approved for Clinical Applications in China

By LabMedica International staff writers
Posted on 03 Jul 2014
Print article
Image: The ACQUITY UPLC system, with technology that provides higher efficiencies with a much wider range of linear velocities, flow rates, and backpressures than optimized HPLC, and eliminates significant time and cost per sample (Photo courtesy of Waters Corporation).
Image: The ACQUITY UPLC system, with technology that provides higher efficiencies with a much wider range of linear velocities, flow rates, and backpressures than optimized HPLC, and eliminates significant time and cost per sample (Photo courtesy of Waters Corporation).
An ultra-performance liquid chromatography – mass spectrometry (UPLC-MS) system has been approved by the Chinese Food and Drug Administration (CFDA) as a medical device for routine diagnostic applications and for screening of neonatal metabolites diseases.

The CFDA approval was granted for the ACQUITY UPLC TQD from Waters Corporation (Milford, MA, USA). A continuation of Waters' commitment to China and to growing clinical LC-MS applications worldwide, this represents the second Waters' mass spectrometer approved for in vitro diagnostic (IVD) applications in China (in 2008, the CFDA (formerly SFDA) approved a neonatal screening solution inclusive of the Waters Quattro micro mass spectrometer).

An UPLC tandem quadrupole mass spectrometry (UPLC/MS/MS) system, the ACQUITY UPLC TQD (tandem quadrupole detector) is a benchtop, ultra-compact, tandem-quadrupole, mass detector-based system designed for routine UPLC/MS/MS analyses and quantitative applications, featuring high levels of MS selectivity, robustness, speed, and accuracy. To maximize the analytical advantages of UPLC, the ACQUITY TQD operates at the highest data acquisition rates. Integrated with the Waters ACQUITY UPLC System, the ACQUITY TQD gives class-leading analytical detection limits, resolution, and sample throughput.

"The approval by the CFDA of ACQUITY UPLC MS/MS system as a medical device is significant for two reasons. First and most importantly, this registration opens the door for millions of Chinese citizens to benefit from the gold standard of LC-MS diagnostic analysis," said Dr. Rohit Khanna, vice president of Worldwide Marketing and Informatics at Waters, "Secondly, this commitment to China's analytical scientists and laboratories reinforces Waters' strategy of expanding applications of our core chromatography and mass spectrometry technologies throughout the world. As of this decision by the CFDA, the ACQUITY UPLC, MS/MS system is registered as a medical device in 29 countries plus the European Economic Area, which includes an additional 30 countries."

Related Links:

Waters Corporation
ACQUITY UPLC TQD


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.